Stock Track | Parabilis Medicines Soars 66.75% Intraday on Successful IPO Pricing Above Expectations

Stock Track

06/11

Shares of Parabilis Medicines (PBLS) soared 66.75% during intraday trading on Wednesday, following its debut on the Nasdaq Global Select Market.

The significant surge is attributed to the company's successful initial public offering, which was priced above expectations. Parabilis Medicines priced its upsized IPO at $20 per share, above its anticipated range of $17 to $19, raising approximately $670 million. In a concurrent private placement, collaboration partner Regeneron Pharmaceuticals agreed to purchase shares for $75 million.

The offering was increased to 33.5 million shares from an initially planned 25 million, reflecting strong investor interest in the clinical-stage biopharmaceutical company as it commenced public trading.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1139874515"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1139874515\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1139874515?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-11 00:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139874515","market":"hk","top_or_hot":-1,"title":"Stock Track | Parabilis Medicines Soars 66.75% Intraday on Successful IPO Pricing Above Expectations","media":"Stock Track","content":"<p>Shares of Parabilis Medicines (PBLS) soared 66.75% during intraday trading on Wednesday, following its debut on the Nasdaq Global Select Market.</p><p>The significant surge is attributed to the company's successful initial public offering, which was priced above expectations. Parabilis Medicines priced its upsized IPO at $20 per share, above its anticipated range of $17 to $19, raising approximately $670 million. In a concurrent private placement, collaboration partner Regeneron Pharmaceuticals agreed to purchase shares for $75 million.</p><p>The offering was increased to 33.5 million shares from an initially planned 25 million, reflecting strong investor interest in the clinical-stage biopharmaceutical company as it commenced public trading.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Parabilis Medicines Soars 66.75% Intraday on Successful IPO Pricing Above Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Parabilis Medicines Soars 66.75% Intraday on Successful IPO Pricing Above Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-11 00:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Parabilis Medicines (PBLS) soared 66.75% during intraday trading on Wednesday, following its debut on the Nasdaq Global Select Market.</p><p>The significant surge is attributed to the company's successful initial public offering, which was priced above expectations. Parabilis Medicines priced its upsized IPO at $20 per share, above its anticipated range of $17 to $19, raising approximately $670 million. In a concurrent private placement, collaboration partner Regeneron Pharmaceuticals agreed to purchase shares for $75 million.</p><p>The offering was increased to 33.5 million shares from an initially planned 25 million, reflecting strong investor interest in the clinical-stage biopharmaceutical company as it commenced public trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PBLS","symbol_name":"Parabilis Medicines","start_time":0,"source_url":"","article_id":"1139874515","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139874515","pubTimestamp":1781110004,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Parabilis Medicines (PBLS) soared 66.75% during intraday trading on Wednesday, following its debut on the Nasdaq Global Select Market.The significant surge is attributed to the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PBLS":"Parabilis Medicines"},"translate_title":"个股追踪|Parabilis Medicines盘中大涨66.75%成功IPO定价超预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PBLS":1},"content_text":"Shares of Parabilis Medicines (PBLS) soared 66.75% during intraday trading on Wednesday, following its debut on the Nasdaq Global Select Market.The significant surge is attributed to the company's successful initial public offering, which was priced above expectations. Parabilis Medicines priced its upsized IPO at $20 per share, above its anticipated range of $17 to $19, raising approximately $670 million. In a concurrent private placement, collaboration partner Regeneron Pharmaceuticals agreed to purchase shares for $75 million.The offering was increased to 33.5 million shares from an initially planned 25 million, reflecting strong investor interest in the clinical-stage biopharmaceutical company as it commenced public trading.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}